TITAN PHARMACEUTICALS INC TTNP Cash Flow

Titan pharmaceuticals inc (TTNP)

CashFlow / TTM

Mar'20	Dec'19	Sep'19	Jun'19	Mar'19	Dec'18	Sep'18	Jun'18	Mar'18	Dec'17	Sep'17	Jun'17	Mar'17	Dec'16	Sep'16	Jun'16	Mar'16	Dec'15	Sep'15	Jun'15	Mar'15	Dec'14	Sep'14	Jun'14	Mar'14	Dec'13	Sep'13	Jun'13	Mar'13	Dec'12	Sep'12	Jun'12	Mar'12	Dec'11	Sep'11	Jun'11	Mar'11
Cash flows from operating activities:
Net loss
-17,525	-16,458	-16,021	-15,263	-10,935	-9,023	-9,179	-11,325	-13,907	-14,307	-12,974	-11,403	3,976	5,135	5,168	5,981	-8,228	-11,279	-9,458	-6,935	-5,496	-2,403	-2,139	-4,000	1,906	9,711	9,641	2,772	-4,016	-15,180	-17,799	-10,589	-15,854	-15,203	0	0	0
Adjustments to reconcile loss to net cash used in operating activities:
Depreciation and amortization
246	244	229	279	328	380	446	438	428	417	406	394	385	377	372	367	362	358	353	354	354	353	353	271	190	107	23	20	17	17	19	22	27	32	0	0	0
Non-cash interest expense
592	613	626	617	574	490	472	349	226	141	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Non-cash gain on termination of royalty purchase agreement
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	8,962	0	0	0	-	-	-	-	-	-	-	-
Amortization of discount on long-term debt
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1,520	0	0	0
Interest on royalty liability
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	-	-	-	-
Non-cash loss on changes in fair value of warrants
0	-	-	-	0	-	-	-	-	-	0	0	0	-	0	0	0	-	-	-	-	-	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Non-cash gain on debt extinguishment
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-4,512	0	0	0	-	-	-	-	1,860	0	0	0	-	-	-	-	-	-	-	-
Non-cash (gain) loss on changes in fair value of warrants
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	-	0	0	0	-	-	-	-
Stock-based compensation
352	572	949	1,209	1,261	1,557	1,702	1,718	1,698	1,687	1,463	1,261	1,128	1,039	1,150	1,040	867	1,026	745	724	708	543	479	429	499	678	1,004	1,348	1,534	2,581	2,602	2,476	2,590	1,177	0	0	0
Finance costs attributable to issuance of warrants
0	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Changes in operating assets and liabilities:
Receivables
-501	-744	93	951	2,025	1,672	591	102	-982	-3,522	-5,817	-4,764	-3,848	-626	2,010	375	1,374	245	-245	733	-597	-850	-447	-108	-14	172	1,060	-59	563	926	733	2,179	1,376	2,495	0	0	0
Inventory
0	-	-	0	0	-	-	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Contract assets
0	-	-	0	0	-	-	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Contract assets
-	-	-	-	-	-	-	-	-	-	-	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Prepaid expenses and other assets
611	547	496	323	277	185	266	104	172	125	-1	80	63	63	16	-1	74	29	-5	22	9	-59	5	13	22	-483	-526	-602	-633	-149	-111	-123	678	542	0	0	0
Accounts payable
137	-125	319	287	692	542	803	548	-83	-2,194	-5,893	-5,346	-3,957	-1,143	2,012	671	388	-250	0	0	0	-	-	-	-	1,351	-157	-1,821	552	-1,022	2,123	3,039	279	2,332	0	0	0
Accrued sales allowances
-686	809	750	830	887	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Other accrued liabilities
0	-	-	0	0	-	-	0	0	-	-	-	-	-	-	-	-	-	-	-	-	172	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Deferred revenue
0	-313	-626	-939	-1,409	313	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Other
30	41	396	126	148	134	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Deferred revenue
-	-	-	-	-	-	-	-	-	-	-	0	0	-	-	-	-	-1,671	-2,583	-3,494	-3,646	-3,646	-3,645	-4,933	-6,219	-9,058	0	0	0	-	-	-	-	-	-	-	-
Net cash provided by (used in) operating activities
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-7,478	-	-7,282	-6,915	-6,334	-5,865	-6,397	-7,181	-9,652	-9,799	0	0	0	-	-	-	-	-	-	-	-
Net cash used in operating activities
-16,349	-15,445	-15,090	-14,033	-11,740	-8,431	-8,625	-9,902	-10,566	-12,677	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	-	0	0	0
Cash flows from investing activities:
Purchases of property and equipment
242	256	489	446	402	416	91	202	207	175	230	149	140	171	173	172	183	133	56	17	23	18	39	30	140	318	329	463	812	1,154	0	0	0	-	-	-	-
Net cash used in investing activities
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-183	-	-56	-17	-23	-18	-39	-30	-140	-318	0	0	0	-	-	-	-	-	-	-	-
Net cash used in investing activities
-242	-256	-489	-446	-402	-416	-91	-202	-207	-175	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	-	-	-	-
Cash flows from financing activities:
Net proceeds from equity offerings
0	-	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Proceeds from issuance of common stock from the exercise of stock options
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	113	0	0	0	-	-	-	-	-	-	-	-
Issuance of common stock from the vesting of restricted shares
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	14	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net proceeds from the exercises of common stock warrants
7,160	1,603	3,992	3,978	3,873	3,268	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1,275	0	0	0	-	-	-	-	-	-	-	-
Payments of long-term debt
-	-	-	-	-	3,000	3,000	3,000	3,000	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	393	135	90	7,336	7,564	0	0	0
Issuance of common stock due to the vesting of restricted shares
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-
Net cash provided by (used in) financing activities
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	9,578	9,578	9,541	9,555	4,888	4,888	2,425	3,813	0	0	0	-	-	-	-	-	-	-	-
Net cash provided by financing activities
18,720	11,268	7,712	14,796	14,225	10,620	5,816	3,729	3,729	6,729	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	-	0	0	0
Net decrease in cash and cash equivalents
0	-	-	-	0	-	-	-	0	-	-	-10,955	5,108	6,149	6,799	7,806	-7,661	-7,613	2,240	2,646	3,184	3,672	-1,548	-2,323	-7,367	-6,304	3,936	7,072	15,298	12,696	2,290	-1,988	1,508	2,226	0	0	0
Supplemental disclosure of cash flow information:
Interest paid
425	432	455	456	457	471	518	532	421	298	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Warrants issued
-	-	-	-	-	-	-	-	757	287	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Purchases of property and equipment included in accounts payable
-	-	-	-	-	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Purchases of property and equipment included in accounts payable
0	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-